|
Printable version |
From: | "G Stolwyk" <stolwyk@wave.co.nz> |
Date: | Sat, 7 Dec 2002 17:05:12 +1300 |
NRT has commenced Trials on Cancer
patients-Leukemia, Cervical and Ovarian.
These Patients were treated with two methods
previously but these failed and now NRT (NOVOGEN) had these patients selected to
undergo a Phenoxodiol treatment immediately followed by a mixture of Pheno. and
Cisplatin.
The patients have advanced cancers and some
have only 4 to 6 months left to live. So, NRT has significant hurdles
to overcome.
---------------------------------------------------------------------------------------------
These trials are being financed by the NRT
shareholders and I have been able to locate a pdf report which is quite clear
about the risks and possible rewards in my opinion:
On page one, reference is made
to NOVOGEN. The latter is actually NRT but quoted on the Nasdaq.
There are minimum values required and hence 1ADR=5 NVGN
shares.
The last line of page one
mentions $US 18 per ADR. Based on say $A =US
56cents, it means that one NVGN (NRT) share is: 18/ 5/ 0.56= $A6.42 against the
current NRT price of $2.18 on the AX.
(Yes we are losing NRT shares at the rate of 1% per
month to the US investors). There has been a small rise lately on the AX and it
is possible that the market has moved out of the "Accumulation" phase.
Presumably, some are waiting for Trial results, but it would be too early for
that; I mentioned that most of these cancers are difficult to
treat.
Please treat that report with care. It has a Disclaimer which needs to be
read. (As always, the reader is responsible for his/her Investment and not the
writer of this article)
It gives a very good description of the compounds NRT is using and the
current state of development.
That is my opinion,
Gerry
NRT Holder.
For after NASDAQ trading, look for
NVGN:
Current price is $US 6.25 per ADR.
For currencies conversions: http://www.ozforex.com.au/cgi-bin/Convert.asp
|
|